Ulrich Martin

4 weeks ago | pipelinereview.com | Ulrich Martin

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, IL, USA I June 1, 2025 I Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body’s...

4 weeks ago | pipelinereview.com | Ulrich Martin

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting TOKYO, Japan & BASKING RIDGE, NJ, USA I June 01, 2025 I Results...

4 weeks ago | pipelinereview.com | Ulrich Martin

Two-thirds (67.4%) of patients treated with IMFINZI-based perioperative regimen remained event-free at two years First and only immunotherapy to demonstrate statistically significant event-free survival in a global Phase III trial in this setting WILMINGTON, DE, USA I June 01, 2025 I Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI®(durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and...

4 weeks ago | pipelinereview.com | Ulrich Martin

First pivotal trial to demonstrate clinical value of monitoring circulating tumor DNA to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer First and only next-generation oral SERD and complete ER antagonist to demonstrate consistent progression-free survival benefit in combination with widely approved CDK4/6 inhibitors in 1st-line advanced breast cancer WILMINGTON, DE, USA I June 01, 2025 I Positive results from the SERENA-6 Phase III trial...

4 weeks ago | pipelinereview.com | Ulrich Martin

Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as...